Unknown

Dataset Information

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.


ABSTRACT:

Background

Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro. Our study aimed to determine the frequency of mutations in four genes: EGFR, ERBB2, ERBB3 and ERBB4 and to investigate whether these mutations affect cellular behaviour and therapy response in vitro and outcomes after adjuvant trastuzumab-based therapy in clinical samples.

Methods

We performed Agena MassArray analysis of 227 HER2+ breast cancer samples to identify the type and frequency of ERBB family mutations. Of these, two mutations, the somatic mutations ERBB4-V721I and E

SUBMITTER: Elster N 

PROVIDER: S-EPMC6047239 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature